The cost-effectiveness of HIV prevention targeting: How much more bang for the buck?
The cost-effectiveness of HIV prevention targeting: How much more bang for the buck?
复制标题
DOI：
10.2105/ajph.86.12.1709
复制
发表时间：
1996-12-01
影响因子：
12.7
通讯作者：
Kahn, JG
中科院分区：
文献类型：
--
作者：
Kahn, JG
背景尽管针对高危人群的人类免疫缺陷病毒（HIV）预防已被广泛讨论，但其益处尚未量化。这种成本效益分析结合了艾滋病毒流行模型、目标人群情景以及预防成本和影响的数据。每年100万美元的预防支出在5年内避免的艾滋病毒感染人数从高危人群的164人到极低风险人群的0.4人不等。40倍到200倍的预防费用差异可以使避免的艾滋病毒感染相等。选择目标似乎带来了很大的好处，在关于预防的分配决定中应予以考虑。
Background. Although the targeting of human immunodeficiency virus (HIV) prevention to high-risk populations has been widely discussed, its benefits have not been quantified.Methods. This analysis of cost-effectiveness combines an HIV epidemic model, target population scenarios, and data on the cost and impact of prevention.Results. The number of HIV infections averted in 5 years with $1 million in annual prevention spending ranges from 164 in high-risk populations to 0.4 in very-low-risk populations. Fortyfold to two-hundred-fold differences in prevention costs could equalize HIV infections averted.Conclusions. Targeting appears to provide substantial benefit and should be considered in allocation decisions about prevention.